Duration of antibiotic therapy in the intensive care unit.

There are certain well defined clinical situations where prolonged therapy is beneficial, but prolonged duration of antibiotic therapy is associated with increased resistance, medicalising effects, high costs and adverse drug reactions. The best way to decrease antibiotic duration is both to stop antibiotics when not needed (sterile invasive cultures with clinical improvement), not to start antibiotics when not indicated (treating colonization) and keep the antibiotic course as short as possible. The optimal duration of antimicrobial treatment for ventilator-associated pneumonia (VAP) is unknown, however, there is a growing evidence that reduction in the length of antibiotic courses to 7-8 days can minimize the consequences of antibiotic overuse in critical care, including antibiotic resistance, adverse effects, collateral damage and costs. Biomarkers like C-reactive protein (CRP) and procalcitonin (PCT) do have a valuable role in helping guide antibiotic duration but should be interpreted cautiously in the context of the clinical situation. On the other hand, microbiological criteria alone are not reliable and should not be used to justify a prolonged antibiotic course, as clinical cure does not equate to microbiological eradication. We do not recommend a 'one size fits all' approach and in some clinical situations, including infection with non-fermenting Gram-negative bacilli (NF-GNB) clinical evaluation is needed but shortening the antibiotic course is an effective and safe way to decrease inappropriate antibiotic exposure.

[1]  M. Kollef,et al.  Short- vs long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. , 2013, Chest.

[2]  J. Jensen,et al.  Procalcitonin increase in early identification of critically ill patients at high risk of mortality* , 2006, Critical care medicine.

[3]  S. Jaber,et al.  Procalcitonin biomarker kinetics fails to predict treatment response in perioperative abdominal infection with septic shock , 2013, Critical Care.

[4]  M. Bonten,et al.  Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. , 2001, American journal of respiratory and critical care medicine.

[5]  V. Nobre,et al.  Procalcitonin Versus C-Reactive Protein for Guiding Antibiotic Therapy in Sepsis: A Randomized Trial* , 2013, Critical care medicine.

[6]  J. Rello,et al.  Recurrent Pseudomonas aeruginosa pneumonia in ventilated patients: relapse or reinfection? , 1998, American journal of respiratory and critical care medicine.

[7]  V L Yu,et al.  Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. , 2000, American journal of respiratory and critical care medicine.

[8]  A. Torres,et al.  A week seems to be weak: tailoring duration of antibiotic treatment in Gram-negative ventilator-associated pneumonia , 2013, Critical Care.

[9]  Peggy Cruse,et al.  Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  G. Webb,et al.  Modeling antibiotic resistance in hospitals: the impact of minimizing treatment duration. , 2007, Journal of theoretical biology.

[11]  M. Kollef,et al.  Antimicrobial stewardship in the intensive care unit: advances and obstacles. , 2009, American journal of respiratory and critical care medicine.

[12]  Marin H Kollef,et al.  A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. , 2004, Chest.

[13]  Michel Wolff,et al.  Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. , 2003, JAMA.

[14]  C. Clec’h,et al.  Differential diagnostic value of procalcitonin in surgical and medical patients with septic shock , 2006, Critical care medicine.

[15]  F. Tubach,et al.  Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial , 2010, The Lancet.

[16]  Antonio Artigas,et al.  What’s new in multidrug-resistant pathogens in the ICU? , 2016, Annals of Intensive Care.

[17]  T. Similowski,et al.  Invasive and Noninvasive Strategies for Management of Suspected Ventilator-Associated Pneumonia , 2000, Annals of Internal Medicine.

[18]  E. Díaz,et al.  Risks for multidrug-resistant pathogens in the ICU , 2014, Current opinion in critical care.

[19]  J. Kline,et al.  Association between timing of antibiotic administration and mortality from septic shock in patients treated with a quantitative resuscitation protocol* , 2011, Critical care medicine.

[20]  W. Peetermans,et al.  Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study , 2009, Intensive Care Medicine.

[21]  A. Torres,et al.  Predicting treatment failure in patients with community acquired pneumonia: a case-control study , 2014, Respiratory Research.

[22]  D. Baram,et al.  Stable patients receiving prolonged mechanical ventilation have a high alveolar burden of bacteria. , 2005, Chest.

[23]  R. Fowler,et al.  Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis , 2011, Critical care.

[24]  A. Torres,et al.  Impact of Candida spp. isolation in the respiratory tract in patients with intensive care unit-acquired pneumonia. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[25]  M. Kollef,et al.  A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia , 2012, Critical Care.

[26]  J. Carratalá,et al.  Early and Late Treatment Failure in Community-Acquired Pneumonia , 2009, Seminars in respiratory and critical care medicine.

[27]  Anthony S McLean,et al.  Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. , 2007, The Lancet. Infectious diseases.

[28]  Richard Pugh,et al.  Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. , 2015, The Cochrane database of systematic reviews.

[29]  Michel Wolff,et al.  Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. , 2017, The Cochrane database of systematic reviews.

[30]  Hajo A. Bruining,et al.  The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. , 1995 .

[31]  M. Niederman,et al.  Resolution of ventilator-associated pneumonia: Prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome* , 2003, Critical care medicine.